Related Experiment Video
Updated: Dec 2, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Genetic variant affecting the myosin light chain 2 related to familial hypertrophic cardiomyopathy
Wilmar Saldarriaga Gil1,2, Laura Alejandra Ávila Vidal3, Manuel Alejandro Vásquez Salguero3
1Health Faculty, Universidad del Valle, Cali, Colombia.
Insights
Familial hypertrophic cardiomyopathy (FHCM) is a genetic heart condition. A likely pathogenic MYL2 gene variant, p.Gly87Ala, was identified in a Colombian patient, underscoring the need for genetic testing.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Genetic Disease Research
Background:
- Familial hypertrophic cardiomyopathy (FHCM) is a prevalent genetic heart disease affecting 1 in 500 individuals.
- FHCM is linked to sarcomere gene variants, with the MYL2 gene implicated in 1-3% of cases.
Observation:
- A 37-year-old Colombian male presented with asymmetric septal hypertrophic cardiomyopathy and ventricular tachycardia.
- He had a family history of FHCM with dominant inheritance, including affected mother and siblings, and sudden deaths in brothers under 35.
Findings:
- Genetic analysis revealed a heterozygous likely pathogenic variant, p.Gly87Ala (rs 397516399), in the MYL2 gene.
- This variant has conflicting interpretations in databases, noted as either uncertain significance or likely pathogenic.
Implications:
- This is the first reported Colombian case of FHCM caused by a MYL2 gene mutation.
- Highlights the critical role of molecular diagnostics, genetic counseling, and bioinformatics in managing FHCM.
Abstract:
Familial hypertrophic cardiomyopathy (FHCM) is a genetic disease characterized by left ventricle (LV) or interventricular septum hypertrophy. FHCM is a common heart disease (affecting 1 out of 500 individuals) associated with genetic variants in genes related to the sarcomere, including the MYL2 (myosin light chain 2) gene that is affected in 1 to 3% of the cases. As described in this report, the genetic mutation p.Gly87Ala, rs 397516399 in the MYL2 gene is likely pathogenic. Reported here is the case of a 37-year-old Colombian man with asymmetric septal hypertrophic cardiomyopathy and ventricular tachycardia. The man had progressive symptomatology, a family history of FHCM with a dominant inheritance pattern, a mother and 2 brothers with FHCM, and 2 brothers who died suddenly before the age of 35. A molecular panel of 17 genes for hypertrophic cardiomyopathy identified a heterozygous variant, p.Gly87Ala, of the MYL2 gene. This variant can be found in Ensembl, dbSNP, and ClinVar, where it has conflicting interpretations: it either has an uncertain significance or it is likely pathogenic. This is the first report of a Colombian case of FHCM secondary to a mutation in the MYL2 gene, highlighting the importance of molecular diagnosis, genetic counseling, and bioinformatic analysis in these patients.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology

